Both CRSP and NTLA are advancing in vivo gene editing therapies targeting large markets, with financial stability supporting ...

Robust efficacy data: ≥90% LDL-C reduction in non-human primates achieved within 48 hours of a single dose of EDIT-401; ≥90% LDL-C reduction in mice with high baseline LDL-C and reduced LDLR function ...

BofA lowered the firm’s price target on Intellia Therapeutics (NTLA) to $30 from $36 and keeps a Buy rating on the shares after the company paused ...

The FDA has released three new guidance documents on cell and gene therapy development, covering clinical trial design and post-market studies.

On Thursday, Editas Medicine Inc. (NASDAQ:EDIT) announced a strategic realignment to focus on in vivo gene editing. In vivo refers to studies or experiments conducted on living organisms or cells ...

Good morning, everyone, and thank you for joining Editas Medicine webinar to unveil our lead development candidate, EDIT-401. This webinar is being recorded and can be accessed in the future through ...

Editas Medicine Inc. (NASDAQ:EDIT) is one of the best performing penny stocks to buy now. On September 5, HC Wainwright reiterated a “Buy” rating on the stock and a $5 price target. The positive ...

New NHP data indicate robust silencing at clinically relevant dose levels and highlight potential best-in-class potency achievable with Chroma's epigenetic editors Chroma's epigenetic editor achieved ...